文章核心观点 - TREMFYA®是首个获批用于治疗溃疡性结肠炎和克罕病的IL-23抑制剂 [1][2][3][4] - TREMFYA®在生物制剂治疗无效或不耐受的克罕病和溃疡性结肠炎患者中,显示出较对照药物更高的内镜缓解率 [1][2] - TREMFYA®在生物制剂治疗无效或不耐受的克罕病和溃疡性结肠炎患者中,显示出良好的安全性 [2] 生物制剂治疗无效或不耐受的克罕病患者 - TREMFYA®在生物制剂治疗无效或不耐受的克罕病患者中,内镜缓解率高于对照药物ustekinumab [2] - 100mg 8周给药方案组为28.1%,200mg 4周给药方案组为28.6%,而ustekinumab组为20.5% [2] 生物制剂/JAK抑制剂治疗无效或不耐受的溃疡性结肠炎患者 - TREMFYA®在生物制剂/JAK抑制剂治疗无效或不耐受的溃疡性结肠炎患者中,内镜缓解率高于安慰剂 [2] - 100mg 8周给药方案组为31.2%,200mg 4周给药方案组为23.9%,而安慰剂组为8% [2] 生物制剂治疗未接受过的克罕病和溃疡性结肠炎患者 - TREMFYA®在生物制剂治疗未接受过的克罕病和溃疡性结肠炎患者中,内镜缓解率高于对照药物 [2] - 克罕病100mg 8周组为44%,200mg 4周组为46.1%,而ustekinumab组为29.8% [2] - 溃疡性结肠炎100mg 8周组为38.1%,200mg 4周组为41.7%,而安慰剂组为20.4% [2]

文章核心观点 - 公司提交了一项针对新诊断多发性骨髓瘤患者的达拉图单抗皮下制剂联合方案的适应症扩展申请 [1] - 该申请基于CEPHEUS III期临床试验数据,显示达拉图单抗皮下制剂联合方案显著提高了微小残留病(MRD)阴性率,并降低了疾病进展或死亡风险 [1] 关于CEPHEUS研究 - CEPHEUS是一项国际随机开放标签III期研究,比较达拉图单抗皮下制剂联合硼替佐米、来那度胺和地塞米松(D-VRd)与标准硼替佐米、来那度胺和地塞米松(VRd)方案 [2][3] - 该研究入组了395例新诊断多发性骨髓瘤患者,其中不适合干细胞移植或计划推迟移植 [2][3] - 主要终点为总体MRD阴性率 [2] 关于PERSEUS研究 - PERSEUS是一项正在进行的随机开放标签III期研究,比较D-VRd方案后续维持治疗与VRd方案后续维持治疗 [4] - 该研究入组709例移植适合的新诊断多发性骨髓瘤患者 [4] - 主要终点为无进展生存期 [4] 关于达拉图单抗 - 达拉图单抗是唯一获批用于皮下给药治疗多发性骨髓瘤的CD38单抗 [5][6] - 达拉图单抗通过结合CD38抑制肿瘤细胞生长,在多项III期临床试验中显示显著改善无进展生存期和/或总生存期 [5][6][7-14] 关于多发性骨髓瘤 - 多发性骨髓瘤是一种无法治愈的血液肿瘤,影响一种白细胞类型-浆细胞 [16][17][18] - 在欧盟,2022年估计有超过35,000例新诊断病例,超过22,700例死亡病例 [19]

文章核心观点 - 强生公司完成收购私人医疗设备公司V-Wave [1] - 此次交易为资产收购,将在2024年第四季度产生约6亿美元的研发费用 [1] - V-Wave专注于心血管疾病治疗解决方案,将成为强生公司医疗技术部门的一部分 [1] - 此次收购预计将稀释强生公司2024年和2025年的经调整每股收益,分别为0.24美元和0.06美元 [1] 公司相关 - 强生公司完成收购私人医疗设备公司V-Wave,支付6亿美元的前期款项 [1] - 此次交易被视为资产收购,将在2024年第四季度产生约6亿美元的研发费用 [1] - V-Wave将成为强生公司医疗技术部门的一部分 [1] 行业相关 - V-Wave专注于心血管疾病治疗解决方案 [1] - 此次收购预计将稀释强生公司2024年和2025年的经调整每股收益,分别为0.24美元和0.06美元 [1]

When selecting dividend-paying stocks, one of the first things that investors look at is, of course, the annual yield.But are high-yield stocks always the best route for income-focused investors? Let’s break it down.Are High-Yield Stocks Best?At a quick glance, a dividend-paying stock with an annual yield above 10% indeed seems like a solid investment from an income-focused standpoint. This is particularly true from a shorter-term perspective, but it’s not always that simple and clear-cut.Dividend yields fl ...

Monday, Johnson & Johnson JNJ said it discontinued the Phase 3 SunRISe-2 trial of TAR-200 in combination with cetrelimab versus concurrent chemoradiotherapy for muscle-invasive urothelial carcinoma (MIBC) patients who are not receiving radical cystectomy.Following an Independent Data Monitoring Committee recommendation and pre-specified interim analysis, SunRISe-2 was discontinued for not showing superiority versus chemoradiation.“We remain confident in the TARIS platform having over $5 billion potential,” ...

Wall Street expects a year-over-year decline in earnings on higher revenues when Johnson & Johnson (JNJ) reports results for the quarter ended September 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on October 15, 2024, might help the stock move higher if these key numbers are better ...

文章核心观点 - 强生公司宣布终止针对肌肉浸润性膀胱癌(MIBC)患者的TAR-200疗法二期临床试验 [1] - 该决定是基于中期分析结果显示TAR-200疗法未能优于现有的化疗放疗治疗 [1] - 尽管遭遇此挫折,强生公司仍有信心获得FDA在2025年初批准TAR-200作为非肌肉浸润性膀胱癌(NMIBC)单药治疗的申请 [1] - 强生公司预计TAR-200平台的销售将超过50亿美元 [1] 行业概况 - 膀胱癌是老年人常见疾病,平均诊断年龄为70岁 [2] - 每年全球约有57万新发病例,其中25%为MIBC,20%高危NMIBC患者可能进展为MIBC [2] - MIBC预后较差,接受治疗5年总生存率为48%-70%,未接受治疗仅5% [2] 公司情况 - 强生公司于2019年通过收购TARIS Biomedical公司获得TARIS平台,包括TAR-200在内的技术 [2] - TAR-200是一种创新的膀胱内给药系统,能持续缓慢给药低剂量吉西他滨,该药物对多种膀胱癌有效 [2]

Johnson & Johnson (JNJ) will report its third-quarter earnings on Oct. 15. The Zacks Consensus Estimate for sales and earnings is pegged at $22.19 billion and $2.19 per share, respectively. The Zacks Consensus Estimate for JNJ’s earnings has declined from $10.07 per share to $10.00 per share for 2024 and from $10.63 per share to $10.62 per share for 2025 over the past 60 days.JNJ Estimate MovementImage Source: Zacks Investment ResearchJNJ's Earnings Surprise HistoryThe healthcare bellwether’s performance ha ...

Johnson & Johnson (JNJ) announced that it has discontinued the phase II field study, which evaluated the company’s investigational antiviral candidate mosnodenvir (formerly JNJ-1802) for the prevention of dengue virus in patients aged between 18 years and 65 years.JNJ decided to stop this study (NCT05201794) as part of the strategic reprioritization of its Communicable Diseases research and development (R&D) portfolio.Year to date, shares of JNJ have risen 2.3% compared with the industry’s growth of 18.5%.I ...

While some investors relish the thrill of high-growth ventures with the potential for significant returns, others prioritize capital preservation and seek out investments that offer security and stability. This approach, known as risk aversion, is a core concept for investors seeking to minimize portfolio volatility and protect their principal investment. Get stock market alerts:Risk-Aversion and Risk-Averse StocksRisk-averse investors prioritize investments with lower potential returns and lower potential ...